Summary:
The purpose of this study is to obtain information on the effectiveness, safety, pharmacokinetics (what the body does to a drug) and pharmacodynamics (what the drug does to the body) of 2 different dose levels and 3 different regimens of subcutaneous (SC) injection of KRYSTEXXA (also called pegloticase), co-administrated with weekly oral doses of Methotrexate (MTX) for gout.
Criteria:- Be 18 to 80 years of age
- Have at least one Tophus due to gout
- Have had at lest 2 or more gout flares in the past 12 months
- Have a presence of chronic gouty arthritis
Qualified Participants May Receive:
- All related study care and invstigational drug at no cost
- Compensation for time and travel